Active Implants nails $26M in new funding commitments

NUsurface meniscus implant--Courtesy of Active Implants

Active Implants has secured $26 million in new investor commitments, and the Tennessee startup says it will use the money to support its signature knee implant through some final regulatory trials.

A first tranche of about $8.7 million is in. View Capital RIA and River Street Management led the financing, which also included other investor firms and private investors, chief financial officer Mike Keenan told FierceMedicalDevices.

Plans call for using the money to help fund completion of a multi-center trial for the company's NUsurface meniscus implant, which continues to enroll patients in Europe and Israel, Active Implants noted. Also, plans are underway for a randomized, pivotal clinical trial that will help support the U.S. regulatory approval process, and the funding will help back that effort, too. Executives, meanwhile, are figuring out the most appropriate regulatory pathway, Keenan explained.

NUsurface is made of a composite polymer and is designed to help patients who have osteoarthritis-related pain and disability, where the condition stems from a previous surgery or meniscus-related problems, the company explains. Separately, Active Implants is developing the TriboFit Buffer hip implant. Both products have a CE mark, previous reports have noted.

As far as NUsurface, the company said the product could potentially meet the needs of patients too old for meniscus repair, but too young for a total knee replacement. They see the potential global annual market surpassing $2 billion, but other competitors are also eyeing the space.

Previously, the Memphis-based company raised $47.3 million in three earlier rounds under a different corporate structure, Keenan said. Formed in 2006, Active Implants employs 15 people.

- read the release

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.